Search - tctmd.com

Displaying 341 - 360 of 3644

Sort: Relevancy | Date

AHA Updates Its Scientific Statement on CIED Infections

News Daily News

AHA Updates Its Scientific Statement on CIED Infections

December 11, 2023

Ukrainian Physicians Like Me Want to Get Back to Doctoring, but Barriers Are Many

News Opinion Off Script

Ukrainian Physicians Like Me Want to Get Back to Doctoring, but Barriers Are Many

Oksana Marchenko, MD

December 07, 2023

New AF Guideline Emphasizes Early Rhythm Control, Elevates Ablation and LAAO

News Daily News

New AF Guideline Emphasizes Early Rhythm Control, Elevates Ablation and LAAO

November 30, 2023

Ischemic Stroke After LAA Closure May Be Less Severe Than on DOACs

News Daily News

Ischemic Stroke After LAA Closure May Be Less Severe Than on DOACs

Michael O'Riordan

November 27, 2023

Looking for a Winner Between Long-term TAVI Trials? Don’t, Experts Urge

News Conference News PCR London Valves 2023

Looking for a Winner Between Long-term TAVI Trials? Don’t, Experts Urge

November 27, 2023

For the Ideal Tricuspid TEER Patient—Look Beyond TRILUMINATE

News Conference News PCR London Valves 2023

For the Ideal Tricuspid TEER Patient—Look Beyond TRILUMINATE

November 20, 2023

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

News Daily News

Symplicity Spyral Approved: FDA Clears Second Renal Denervation System

November 20, 2023

Left Bundle Branch Area Pacing May Lessen Arrhythmias in CRT Patients

News Conference News AHA 2023

Left Bundle Branch Area Pacing May Lessen Arrhythmias in CRT Patients

November 15, 2023

Seeing Sticker Price for HFrEF Meds Opens Door to Discussions

News Conference News AHA 2023

Seeing Sticker Price for HFrEF Meds Opens Door to Discussions

November 14, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

News Conference News AHA 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

November 12, 2023

Dropping Aspirin Cuts Strokes, Bleeds, Hospital Stays in LVAD Patients: ARIES-HCM3

News Conference News AHA 2023

Dropping Aspirin Cuts Strokes, Bleeds, Hospital Stays in LVAD Patients: ARIES-HM3

November 11, 2023

Leadless Pacemaker Prototype Uses Heart’s Energy to Partly Power Device

News Conference News AHA 2023

Leadless Pacemaker Prototype Uses Heart’s Energy to Partly Power Device

Michael O'Riordan

November 11, 2023

New Carotid Stent Systems Associated With Low Stroke Risk

News Conference News VIVA 2023

New Carotid Stent Systems Associated With Low Stroke Risk

November 09, 2023

FDA Approves Paradise Renal Denervation System: What Comes Next?

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

November 08, 2023

What’s Going to Be Hot at AHA 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

November 07, 2023

MitraClip G4 Data Impress, but Some Question the Reproducibility: EXPAND G4

News Conference News TCT 2023

MitraClip G4 Data Impress, but Some Question the Reproducibility: EXPAND G4

Yael L. Maxwell

November 02, 2023

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

News Conference News TCT 2023

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

November 02, 2023

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

News Conference News VIVA 2023

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

November 01, 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.